Sino Biological, Inc., a global biotechnology company specializing in recombinant proteins and antibodies, has launched two dedicated target protein collections designed to support AI-driven discovery: AI-Trusted Proteins and AI-Qualified Proteins. The collections address a critical bottleneck in AI-accelerated drug discovery: the need for well-characterized experimental reagents to evaluate molecules designed computationally.
AI-Trusted Proteins have been used in AI-focused company validation projects, with some featured in published research. This collection covers more than 600 targets and 960 individual proteins, with characterization data that may include SPR, BLI, ELISA, cell-based activity assays, SEC-HPLC, and SEC-MALS analyses. AI-Qualified Proteins offer experimentally characterized binding activity, including SPR/BLI validation data, and specialized formats such as biotinylated proteins. With over 680 targets and 1,700 individual proteins, this collection provides a broad selection for evaluating AI-designed molecules.
The collections are underpinned by Sino Biological's 4S System—Scale, Scope, Speed, and Supply—which provides the resource breadth, production capabilities, and supply reliability required for AI-driven discovery. Scale encompasses more than 11,000 recombinant target proteins, including over 1,200 biotinylated proteins. Scope covers membrane, extracellular, and intracellular proteins, as well as mutants and diverse formats. Speed ensures rapid, scalable production and efficient order processing with local inventory. Supply guarantees lot-to-lot consistency, multi-lot availability, and reliable long-term supply.
"AI-driven discovery depends on reliable experimental resources to evaluate designed molecules and guide subsequent research decisions," said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. "By combining AI-Trusted and AI-Qualified target proteins with our 4S System, we aim to provide researchers with well-characterized target resources, broad coverage, and dependable supply to support AI-driven protein and antibody discovery."
The announcement matters because AI-driven protein and antibody discovery is only as good as the experimental validation behind it. Without access to well-characterized target proteins, AI-designed molecules cannot be reliably tested, slowing the translation of computational predictions into therapeutic candidates. Sino Biological's collections directly address this gap by offering proteins with demonstrated performance in AI research and experimentally verified binding activity. The 4RISE™ AI Lab Validation Solution further integrates these target proteins with high-throughput expression, binding characterization, developability assessment, and functional validation, providing end-to-end wet-lab support to move AI-designed molecules from prediction to evidence.
Additionally, Sino Biological has developed a therapeutic target directory covering 12 therapeutic areas and more than 100 diseases, enabling researchers to explore relevant targets by area or disease. The company serves researchers in more than 90 countries. More information is available at www.sinobiological.com, and the original release can be viewed via NEWMEDIAWIRE.


